Vertex Pharmaceuticals (VRTX) Q4 2025 (USD): Adj. EPS 5.03 (exp. 5.11), Revenue 3.19bln (exp. 3.18bln); FY26 revenue view 12.95-13.1bln (exp. 13.02bln)

Vertex Pharmaceuticals missed its adjusted EPS expectations, slightly underperforming the consensus, which could signal pressure on sentiment toward the stock.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Arista Networks Inc. (ANET) Q4 2025 (USD): Adj. EPS 0.82 (exp. 0.76), Revenue 2.49bln (exp. 2.38bln)

Rivian Automotive Inc. (RIVN) Q4 2025 (USD) Adj. EPS -0.54 (exp. -0.69), Revenue 1.29bln (exp. 1.26bln)

Vertex Pharmaceuticals (VRTX) Q4 2025 (USD): Adj. EPS 5.03 (exp. 5.11), Revenue 3.19bln (exp. 3.18bln); FY26 revenue view 12.95-13.1bln (exp. 13.02bln)

Applied Materials Inc. (AMAT) Q1 2026 (USD): Adj. EPS 2.38 (exp. 2.21), Revenue 7.01bln (exp. 6.87bln), Adj. net income 1.9bln (exp. 1.75bln)

Airbnb Inc. (ABNB) Q4 2025 (USD) EPS 0.56 (exp. 0.66), Revenue 2.78bln (exp. 2.71bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

However, the revenue beat suggests some stability in operations, while guidance for FY26 aligns closely with expectations, indicating management’s confidence amidst mixed results. Investors should monitor how this affects broader biotech sentiment and trading activity in VRTX going forward.

Related headlines

The whole workspace, free to try.

Try it free